News articles about Viveve Medical (NASDAQ:VIVE) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Viveve Medical earned a coverage optimism score of 0.07 on Accern’s scale. Accern also assigned headlines about the company an impact score of 44.5261980727548 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern Sentiment’s rankings:
- What’s Ahead for Viveve Medical, Inc. (VIVE) After Reaching All-Time Low? (goldmanblog.com)
- An Eye on Profitability Ratios Viveve Medical, Inc. (VIVE) (nasdaqfortune.com)
- For Sale VIVEVE SYSTEM VIVGE01 Viveve Generator (dotmed.com)
- Viveve Medical (VIVE) versus Helius Medical Technologies (HSDT) Head to Head Review (topix.com)
- Helius Medical Technologies (HSDT) versus Viveve Medical (VIVE) Head to Head Review (americanbankingnews.com)
Several research firms have recently weighed in on VIVE. Mizuho restated a “buy” rating and set a $10.00 price objective on shares of Viveve Medical in a research note on Tuesday, March 20th. Maxim Group reaffirmed a “buy” rating and set a $11.00 target price on shares of Viveve Medical in a report on Friday, March 16th. ValuEngine downgraded shares of Viveve Medical from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Ladenburg Thalmann Financial Services reissued a “buy” rating on shares of Viveve Medical in a report on Thursday, January 4th. Finally, Northland Securities started coverage on shares of Viveve Medical in a research report on Friday, January 5th. They issued an “outperform” rating and a $8.00 target price for the company. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $10.00.
Viveve Medical (NASDAQ:VIVE) last announced its quarterly earnings results on Thursday, March 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.06). Viveve Medical had a negative net margin of 241.75% and a negative return on equity of 328.38%. The business had revenue of $5.10 million during the quarter, compared to analyst estimates of $5.09 million. equities research analysts anticipate that Viveve Medical will post -1.44 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by BBNS and is the sole property of of BBNS. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://baseballnewssource.com/2018/04/06/viveve-medical-vive-receiving-somewhat-favorable-press-coverage-study-shows/2037821.html.
Viveve Medical Company Profile
Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable accessories.
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.